Grade: C — Some Red Flags, Investigate
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (filed Feb 4, 2026) + Yahoo Finance
Auditor: Deloitte & Touche LLP — Clean opinion (unqualified)
One-line verdict: GEHC's three automated fails — AR outpacing revenue for two years, cash covering only 43% of debt, and goodwill at 141% of equity — warrant investigation but not elimination. The M-Score at -2.35 is borderline but still below the -2.22 manipulation threshold. The AR growth pattern aligns with GEHC's business model of selling high-value medical imaging equipment with extended payment terms. The goodwill stems from the GE spin-off, not aggressive acquisitions. The real concern from the 10-K is the $245 million tariff impact on operating income, declining margins in Patient Care Solutions, and continued China market pressure. We set the grade at C: there are legitimate items to monitor, but no evidence of manipulation.
| Metric | Result |
|---|---|
| Red Flags | **3** |
| Watch Items | **1** |
| Checks Completed | **17/18** |
| Beneish M-Score | **-2.35** (borderline clean) |
| Altman Z-Score | **2.07** (grey zone) |
| Piotroski F-Score Prob | **0.53%** (low) |
| Auditor | Deloitte & Touche LLP — Unqualified opinion |
The Business: A MedTech Giant Freshly Spun Off
GE HealthCare Technologies was spun off from General Electric (now GE Aerospace) on January 3, 2023. It operates through four segments: Imaging ($9.2B), Advanced Visualization Solutions ($5.4B), Patient Care Solutions ($3.1B), and Pharmaceutical Diagnostics ($2.9B). The company sells medical imaging equipment (MRI, CT, ultrasound), patient monitoring systems, and contrast agents used in diagnostic imaging.
This is a capital equipment business with long sales cycles, significant installation and service components, and multi-element revenue contracts — all of which create complexity in revenue recognition and working capital timing.
Profitability: Steady Growth with Margin Compression
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|---|
| Revenue | $18.3B | $19.6B | $19.7B | $20.6B | +4.8% YoY |
| Net Income | $1.9B | $1.6B | $2.0B | $2.1B | +4.6% YoY |
| Gross Margin | 39.1% | 40.5% | 41.7% | 40.0% | Down -1.7pp |
| Net Margin | 10.4% | 8.0% | 10.1% | 10.1% | Stable |
| Operating Margin | — | — | 13.3% | 13.4% | Flat |
Revenue grew 4.8% as reported and 3.5% organically, driven by "strong growth in PDx, Imaging, and AVS revenues." The 10-K states: "Sales of products increased 4.5% or $586 million" and "Sales of services increased 5.6% or $368 million primarily driven by growth in new and existing customer contractual agreements."
However, gross margin contracted 170 basis points to 40.0%. The 10-K is explicit about the cause: "Cost of products sold increased $671 million or 220 basis points as a percent of Sales of products. The increase as a percent of sales was driven by cost inflation, including the impact of incremental tariffs, and investment in design follow-through."
The tariff impact was substantial: "tariffs materially impacted our Operating income by approximately $245 million and cash flows by approximately $285 million for the year ended December 31, 2025, primarily the bilateral U.S. and Chinese tariffs."
Cash Flow: Adequate but Not Exceptional
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Cash Flow | $2.1B | $2.1B | $2.0B | $2.0B |
| Net Income | $1.9B | $1.6B | $2.0B | $2.1B |
| **CFFO / Net Income** | **1.10** | **1.34** | **0.98** | **0.95** |
| Free Cash Flow | $1.8B | $1.7B | $1.6B | $1.5B |
CFFO/NI of 0.95 is acceptable — close to 1.0 means earnings and cash are broadly aligned. The slight decline from prior years reflects working capital timing in a capital equipment business with long delivery cycles.
FCF of $1.5 billion, while declining from $1.8B in FY2022, remains positive and supports debt reduction. The 10-K notes that "Interest and other financial charges net decreased $64 million primarily driven by debt repayment and continued optimization."
Balance Sheet: Spin-Off Legacy
| Item | FY2025 | Notes |
|---|---|---|
| Cash | **$4.5B** | Up from $2.9B in FY2024 |
| Total Debt | **$10.5B** | Up from $9.4B (NMP acquisition) |
| Cash minus Debt | **-$6.0B** | Net debt position |
| Goodwill | $13.5B | Primarily from GE spin-off allocation |
| Intangibles | $1.1B | Declining via amortization |
| **Goodwill + Intangibles / Equity** | **141%** | Fails threshold |
| Debt/EBITDA | **2.8x** | Healthy |
| Interest Coverage | **6.3x** | Adequate |
The goodwill of $13.5 billion is a spin-off legacy — when GE separated HealthCare, substantial goodwill was allocated to the new entity. This is not from GEHC management making aggressive acquisitions. Goodwill grew modestly (+3% YoY) due to the Nihon Medi-Physics (NMP) acquisition.
Deloitte's Critical Audit Matter focused on "Revenue Recognition — Allocation of the Transaction Price to Each Performance Obligation," noting that "contracts for the sale of products and services often include multiple distinct performance obligations" and that the "allocation of the transaction price to each performance obligation involves judgments and estimates." This is a standard MedTech complexity, not a manipulation signal.
The 18-Point Screening
Revenue Quality
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO | ✅ | 66 days, +3 days YoY. Modest increase |
| A2 | AR vs Revenue | ❌ | AR outpaced revenue for 2 consecutive years |
| A3 | Revenue vs CFFO | ✅ | Revenue +4.8%, CFFO +1.8%. Cash follows revenue |
A2 fails because accounts receivable growth exceeded revenue growth for two years. In a medical equipment business with large government and hospital customers, AR timing can swing based on contract milestones, installation completions, and government payment cycles. The DSO increase from 63 to 66 days is not alarming. The China market, where GEHC generated $2.3 billion in revenue, is known for extended payment terms, particularly from government hospitals.
Expense Quality
| # | Check | Result | Detail |
|---|---|---|---|
| B1 | Inventory | ✅ | Inventory +15.2% vs COGS +7.9%. Normal for equipment business ramping production |
| B2 | CapEx | ⚠️ | CapEx growth 20.2% is >2x revenue growth 4.8% |
| B3 | SG&A | ✅ | SG&A/Gross Profit = 51.2%. Normal for MedTech |
| B4 | Gross Margin | ✅ | 40.0%, -1.7pp YoY. Decline explained by tariffs |
B2 triggers a watch but the 10-K explains the CapEx increase: GEHC is investing in "engineering costs for design follow-through on new product introductions and product lifecycle maintenance" ($490 million vs $405 million prior year). SG&A actually decreased $44 million, partially offset by "increased investment in commercial teams and the acquisition of NMP."
Cash Flow Quality
| # | Check | Result | Detail |
|---|---|---|---|
| C1 | CFFO vs NI | ✅ | Ratio 0.95. Profits backed by cash |
| C2 | FCF | ✅ | $1.5B, FCF/NI = 0.72 |
| C3 | Accruals | ✅ | 0.3%. Very low accruals — clean |
| C4 | Cash vs Debt | ❌ | Cash $4.5B covers only 43% of debt $10.5B |
C4 fails but the situation is improving: cash grew from $2.9B to $4.5B while debt only increased from $9.4B to $10.5B (NMP acquisition). Interest coverage of 6.3x is comfortable. The company is actively paying down debt — "Interest and other financial charges net decreased $64 million primarily driven by debt repayment."
Balance Sheet
| # | Check | Result | Detail |
|---|---|---|---|
| D1 | Goodwill | ❌ | Goodwill + Intangibles $14.6B = 141% of equity |
| D2 | Leverage | ✅ | Debt/EBITDA 2.8x. Healthy |
| D3 | Soft Assets | ✅ | Other assets -17.1% vs revenue +4.8%. Normal |
| D4 | Impairment | — | No data |
Acquisition Risk
| # | Check | Result | Detail |
|---|---|---|---|
| E1 | Serial Acquirer | ✅ | FCF after acquisitions positive |
| E2 | Goodwill Surge | ✅ | Goodwill + Intangibles +3% YoY. Normal (NMP) |
M-Score
| # | Check | Result | Detail |
|---|---|---|---|
| F1 | M-Score | ✅ | -2.35, below -2.22 threshold. Borderline clean |
The M-Score at -2.35 is close to the -2.22 threshold but still passes. The DEPI (Depreciation Index) at 1.176 is the highest component, suggesting depreciation policy may be slightly less conservative, but it is within normal bounds. All other components are unremarkable.
Key Risks from the 10-K
1. Tariff Impact — $245 Million Operating Income Hit
The 10-K is unusually specific: "tariffs materially impacted our Operating income by approximately $245 million and cash flows by approximately $285 million." This came from "primarily the bilateral U.S. and Chinese tariffs and U.S. tariffs on all other global import suppliers." The company warns: "Should the tariffs continue at formally communicated levels, we expect to continue to see a material impact to our financial results." Mitigation actions are underway but "we do not expect that our mitigation actions will fully offset the additional costs."
2. China Market Pressure
China region revenues declined 4.6% to $2.3 billion, "with declines in Imaging, AVS, and PCS revenues." The 10-K warns of "increased competition from local companies and the prevalence of Volume Based Procurement policies, both of which have impacted our orders and revenues and may continue to do so." There is also risk that "negative sentiment towards U.S. companies influences the purchasing decisions of global customers."
3. Patient Care Solutions Margin Collapse
PCS segment EBIT plunged 39.6% — from $347 million to $209 million — on only a 1.2% revenue decline. The 10-K attributes this to "unfavorable mix, cost inflation, including the impact of incremental tariffs, and a decline in sales volume." PCS margin dropped from 11.1% to 6.8%. This is the weakest segment and bears monitoring.
4. Russia/Ukraine Exposure
GEHC maintains $214 million in assets related to Russia/Ukraine and generated $353 million in revenue from these countries. The 10-K notes ongoing licensing requirements and uncertainties about repatriation of earnings. While not material to the overall business, this is a regulatory and reputational risk.
5. Right-to-Repair and ISOs
The 10-K highlights growing competition from independent service organizations (ISOs) and "right-to-repair laws in the U.S. and elsewhere" that could impact the service business. "A copyright act exemption allows third-party repair companies to circumvent OEM copyright protections on software in medical imaging devices." GEHC's service business is a key margin contributor.
Summary
Grade: C. Monitor the AR pattern, tariff exposure, and China headwinds.
GEHC's financial statements show a fundamentally healthy MedTech business: $20.6B revenue growing 4.8%, $1.5B FCF, M-Score clean at -2.35, accruals ratio of just 0.3%, and no evidence of earnings manipulation. The auditor issued a clean opinion with one Critical Audit Matter on revenue recognition allocation — standard for a multi-element contract business.
The automated F-grade was driven by spin-off legacy goodwill (141% of equity), AR outpacing revenue (explainable by MedTech contract timing), and low cash coverage of debt (improving). These are structural characteristics, not manipulation signals.
The real risks from the 10-K are operational: $245 million tariff hit with no full offset expected, China market shrinking, PCS segment margin collapsing from 11.1% to 6.8%, and growing right-to-repair pressure on the service business. These deserve investor attention but are business risks, not accounting red flags.
**Disclaimer**: This report is based on GE HealthCare's FY2025 10-K (SEC EDGAR, filed Feb 4, 2026) and public financial data. This is NOT investment advice.
Data: SEC EDGAR 10-K + Yahoo Finance
Auditor: Deloitte & Touche LLP (Unqualified opinion)